Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

City of Hope cures oldest person of blood cancer and achieves HIV remission

City of Hope, one of the largest cancer research and treatment organizations in the United States, treated the oldest person to be cured of a blood cancer and then achieve remission for HIV after receiving a blood stem cell transplant from a donor with a rare genetic mutation.

15 Feb 2024

New Blood Cancer Healing Center poised to redefine care standards

The Blood Cancer Healing Center, located at 3229 Burnet Avenue in Uptown Cincinnati, is poised to redefine care standards by offering comprehensive patient support and innovative treatments under one roof.

15 Feb 2024

Researchers develop enhanced immunotherapy for multiple myeloma treatment

Immunotherapy is already improving treatment options for many cancer types, but research groups keep exploring ways to boost the body's immune response against the tumor.

14 Feb 2024

Novel approach improves CAR T-cell therapy efficacy against acute myeloid leukemia

St. Jude Children's Research Hospital scientists improved chimeric antigen receptor (CAR) T–cell immunotherapy for acute myeloid leukemia (AML), demonstrating better efficacy in the lab.

12 Feb 2024

FDA’s plan to ban hair relaxer chemical called too little, too late

In April, a dozen years after a federal agency classified formaldehyde a human carcinogen, the Food and Drug Administration is tentatively scheduled to unveil a proposal to consider banning the chemical in hair-straightening products.

8 Feb 2024

Single-cell study reveals clues to epigenetic drug response in Myelodysplastic Syndrome

Researchers from the Josep Carreras Leukaemia Research Institute, spearheaded by the Cancer Epigenetics group led by Dr. Manel Esteller, described the effects of chemotherapy at the single cell resolution in the bone marrow of Myelodysplastic Syndrome patients.

6 Feb 2024

Proteogenomics provides clues about drug response in acute myeloid leukemia

Doctors have nearly a dozen new targeted drugs to treat patients with acute myeloid leukemia, or AML, yet three of four patients still die within five years.

6 Feb 2024

Combination treatments reduce blood pressure in patients taking ibrutinib

Combination treatments with two or more blood pressure drugs can significantly reduce blood pressure in patients taking ibrutinib, according to a new study published in Blood Advances.

5 Feb 2024

Small-molecule A485 mobilizes white blood cells on demand

New study reveals a small molecule that can selectively mobilize white blood cells, offering potential treatments for diseases with abnormal leukocyte counts.

3 Feb 2024

Proteogenomics reveals new target for beating drug resistance in acute myeloid leukemia

Doctors have nearly a dozen new targeted drugs to treat patients with acute myeloid leukemia, or AML, yet three of four patients still die within five years.

2 Feb 2024

Next-gen BTK degrader could help overcome treatment resistance in chronic lymphocytic leukemia

New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations has identified a next-generation BTK degrader that could help overcome treatment resistance in chronic lymphocytic leukemia (CLL) and related blood cancers.

1 Feb 2024

RNA sequencing analysis feasible for diagnosis of molecular subtypes in pediatric B-ALL

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, representing more than 30% of all pediatric cases.

29 Jan 2024

Dr. Chao Ma: Pioneering 'Leukemia-on-a-Chip' for CAR T Cell Therapy at SLAS 2024

NewsMedical speaks with Chao Ma, Ph.D. a Research Assistant Professor at New York University Tandon School of Engineering, ahead of his presentation at SLAS 2024.

From Society for Laboratory Automation and Screening (SLAS) 29 Jan 2024

Gene activity plays key role in immune cell production, study shows

As people age or become ill, their immune systems can become exhausted and less capable of fighting off viruses such as the flu or COVID-19.

27 Jan 2024

Penn analysis shows low risk of secondary cancers following CAR T cell therapy

The development of any type of second cancer following CAR T cell therapy is a rare occurrence, as found in an analysis of more than 400 patients treated at Penn Medicine, researchers from the Perelman School of Medicine at the University of Pennsylvania reported today in Nature Medicine.

24 Jan 2024

Unintentional weight loss linked to increased risk of cancer diagnosis

Unintentional weight loss is associated with an increase in the risk of a cancer diagnosis within the coming year, according to a study from Dana-Farber Cancer Institute.

23 Jan 2024

Cord blood-derived CAR NK cell therapy targeting CD19 shows promise for treating patients with B-cell malignancies

Researchers from The University of Texas MD Anderson Cancer Center reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19.

18 Jan 2024

RBM5 identified as key regulator of HOXA9 in acute myeloid leukemia

The protein HOXA9 is overexpressed in most acute myeloid leukemia (AML) cases and is associated with poor patient outcomes.

12 Jan 2024

UTEP researchers unveil promising new weapon against leukemia and lymphoma

Researchers at The University of Texas at El Paso have identified a novel pharmaceutical compound that successfully kills leukemia and lymphoma cancer cells, potentially paving the way for new forms of therapy.

11 Jan 2024

Research discovers fibronectin's role in BRAF-mutant thyroid cancer resistance

New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, PhD, could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF gene -; a mutation also responsible for some types of melanoma, colorectal cancer, leukemia, lymphoma, and ovarian cancer.

10 Jan 2024